(0.26%) 5 113.17 points
(0.20%) 38 318 points
(0.30%) 15 976 points
(-0.98%) $83.03
(4.94%) $2.02
(0.06%) $2 348.50
(0.24%) $27.60
(4.15%) $960.35
(-0.18%) $0.933
(-0.28%) $10.99
(-0.48%) $0.797
(1.72%) $93.45
Quarter results today
(amc 2024-04-29)
Expected move: +/- 2.26%
Live Chart Being Loaded With Signals
Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine...
Stats | |
---|---|
Šios dienos apimtis | 368 240 |
Vidutinė apimtis | 1.27M |
Rinkos kapitalizacija | 129.13B |
EPS | $0 ( 2024-01-30 ) |
Kita pelno data | ( $2.35 ) 2024-05-06 |
Last Dividend | $0.750 ( 2023-09-28 ) |
Next Dividend | $0 ( N/A ) |
P/E | 41.11 |
ATR14 | $0.264 (0.08%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-21 | Stiles Spencer S | Buy | 203 | Common Stock |
2024-03-21 | Stiles Spencer S | Sell | 3 796 | Common Stock |
2024-03-21 | Stiles Spencer S | Sell | 203 | Dividend Equivalents |
2024-03-21 | Pierce James Andrew | Buy | 203 | Common Stock |
2024-03-21 | Pierce James Andrew | Sell | 4 412 | Common Stock |
INSIDER POWER |
---|
-59.40 |
Last 100 transactions |
Buy: 383 181 | Sell: 1 508 551 |
Tūris Koreliacija
Stryker Corp Koreliacija
10 Labiausiai teigiamai susiję koreliacijos |
---|
10 Labiausiai neigiamai susiję koreliacijos |
---|
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
Stryker Corp Koreliacija - Valiuta/Žaliavos
Stryker Corp Finansinės ataskaitos
Annual | 2023 |
Pajamos: | $20.50B |
Bruto pelnas: | $13.06B (63.70 %) |
EPS: | $8.34 |
FY | 2023 |
Pajamos: | $20.50B |
Bruto pelnas: | $13.06B (63.70 %) |
EPS: | $8.34 |
FY | 2022 |
Pajamos: | $18.45B |
Bruto pelnas: | $11.58B (62.76 %) |
EPS: | $6.23 |
FY | 2021 |
Pajamos: | $17.11B |
Bruto pelnas: | $10.97B (64.11 %) |
EPS: | $5.31 |
Financial Reports:
No articles found.
Stryker Corp Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0.695 (N/A) |
$0.750 (N/A) |
$0.750 (N/A) |
$0.750 (N/A) |
$0.750 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | $0.00150 | 1991-12-24 |
Last Dividend | $0.750 | 2023-09-28 |
Next Dividend | $0 | N/A |
Payout Date | 2023-10-31 | |
Next Payout Date | N/A | |
# dividends | 75 | -- |
Total Paid Out | $25.16 | -- |
Avg. Dividend % Per Year | 0.67% | -- |
Score | 5.39 | -- |
Div. Sustainability Score | 10.00 | |
Div.Growth Potential Score | 6.08 | |
Div. Directional Score | 9.57 | -- |
Year | Amount | Yield |
---|---|---|
1991 | $0.00150 | 0.08% |
1992 | $0.00100 | 0.02% |
1993 | $0.00213 | 0.04% |
1994 | $0.00225 | 0.06% |
1995 | $0.00275 | 0.06% |
1996 | $0.00625 | 0.10% |
1997 | $0.0275 | 0.37% |
1998 | $0.00750 | 0.08% |
1999 | $0.0325 | 0.24% |
2000 | $0.0400 | 0.23% |
2001 | $0.0500 | 0.21% |
2002 | $0.0600 | 0.21% |
2003 | $0.0700 | 0.21% |
2004 | $0.0900 | 0.22% |
2005 | $0.110 | 0.23% |
2006 | $0.220 | 0.49% |
2007 | $0.330 | 0.60% |
2008 | $0.400 | 0.54% |
2009 | $0.250 | 0.61% |
2010 | $0.630 | 1.21% |
2011 | $0.753 | 1.38% |
2012 | $0.904 | 1.77% |
2013 | $1.100 | 1.97% |
2014 | $1.260 | 1.69% |
2015 | $1.415 | 1.51% |
2016 | $1.565 | 1.74% |
2017 | $1.745 | 1.46% |
2018 | $1.930 | 1.22% |
2019 | $2.14 | 1.38% |
2020 | $2.36 | 1.12% |
2021 | $2.59 | 1.08% |
2022 | $2.84 | 1.06% |
2023 | $2.25 | 0.92% |
2024 | $0 | 0.00% |
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
LOMA | Dividend Knight | 2023-06-30 | Quarterly | 2 | 5.23% | 8.53 |
PHK | Dividend Royal | 2023-11-10 | Monthly | 22 | 6.88% | 8.50 |
JQC | Dividend Royal | 2023-11-14 | Monthly | 22 | 6.56% | 8.50 |
PCF | Dividend King | 2023-12-18 | Monthly | 38 | 7.05% | 8.50 |
PVL | Dividend King | 2023-11-15 | Monthly | 14 | 9.37% | 8.50 |
NCV | Dividend Royal | 2024-02-09 | Monthly | 22 | 7.68% | 8.50 |
SBR | Dividend Royal | 2023-11-14 | Monthly | 38 | 7.74% | 8.50 |
MTR | Dividend Diamond | 2023-10-30 | Monthly | 39 | 10.10% | 8.50 |
PDI | Dividend Royal | 2023-11-10 | Monthly | 13 | 7.86% | 8.50 |
ZTR | Dividend King | 2024-02-09 | Monthly | 37 | 8.35% | 8.50 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.154 | 1.500 | 6.91 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.0793 | 1.200 | 7.36 | 8.83 | [0 - 0.3] |
returnOnEquityTTM | 0.179 | 1.500 | 9.12 | 10.00 | [0.1 - 1] |
payoutRatioTTM | 0.360 | -1.000 | 6.40 | -6.40 | [0 - 1] |
currentRatioTTM | 1.580 | 0.800 | 7.10 | 5.68 | [1 - 3] |
quickRatioTTM | 0.861 | 0.800 | 9.64 | 7.71 | [0.8 - 2.5] |
cashRatioTTM | 0.375 | 1.500 | 9.03 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.326 | -1.500 | 4.57 | -6.86 | [0 - 0.6] |
interestCoverageTTM | 69.43 | 1.000 | 10.00 | 10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | 9.77 | 2.00 | 6.74 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 8.25 | 2.00 | 5.87 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.699 | -1.500 | 7.20 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.637 | 1.000 | 2.72 | 2.72 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.190 | 1.000 | 8.21 | 8.21 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.286 | 1.000 | 9.52 | 9.52 | [0.2 - 2] |
assetTurnoverTTM | 0.514 | 0.800 | 9.91 | 7.93 | [0.5 - 2] |
Total Score | 13.07 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 40.29 | 1.000 | 6.03 | 0 | [1 - 100] |
returnOnEquityTTM | 0.179 | 2.50 | 9.44 | 10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 8.25 | 2.00 | 7.25 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 0.924 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 9.77 | 2.00 | 6.74 | 10.00 | [0 - 30] |
payoutRatioTTM | 0.360 | 1.500 | 6.40 | -6.40 | [0 - 1] |
pegRatioTTM | 0.223 | 1.500 | -1.848 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.181 | 1.000 | 7.97 | 0 | [0.1 - 0.5] |
Total Score | 6.08 |
Stryker Corp
Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. This segment also offers spinal implant products comprising cervical, thoracolumbar, and interbody systems that are used in spinal injury, deformity, and degenerative therapies. The MedSurg and Neurotechnology segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical device products that are used in various medical specialties. This segment also provides neurotechnology products, which include products used for minimally invasive endovascular techniques; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke; and craniomaxillofacial implant products, including cranial, maxillofacial, and chest wall devices, as well as dural substitutes and sealants. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Kalamazoo, Michigan.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.